Summit Therapeutics Trades Below AstraZeneca's $18.36
AstraZeneca's $2 billion investment in Summit Therapeutics at $18.36 per share is now worth less on paper, with the stock trading at $14.63 as 26.3% short interest bets against ivonescimab and Chinese
SMMT Trades Below AstraZeneca's $18 Entry Price
NEW YORK, October 17 —
Eighteen days after AstraZeneca committed $2 billion to Summit Therapeutics Inc. (SMMT) at an implied $18.36 per share, the stock trades at $14.63. Short sellers holding 26.3% of the float are effectively calling the strategic investor wrong, raising questions about whether dilution mechanics in the convertible, skepticism about Chinese clinical data, or HARMONi-3 trial risk is driving the gap.
- AstraZeneca invested $2 billion at an implied $18.36 per share; SMMT now trades at $14.63.
- Short interest: 26.3% of the float, concentrated against an 80.9% insider-owned share base.
- Pre-deal cash position: $690 million versus $458 million in annual operating outflows, implying under 18 months of runway.
Below the Partner's Own Cost Basis
Summit Therapeutics is developing ivonescimab, a bispecific antibody in Phase III trials for non-small cell lung cancer and colorectal cancer that blocks PD-1, the same checkpoint targeted by Keytruda, and cuts off blood supply to tumors. Pre-revenue and burning $458 million annually against a $690 million cash position, Summit also filed a registered stock offering on the same day it reported quarterly results in July. AstraZeneca's $2 billion convertible preferred investment, per the September 29 8-K, addressed that runway pressure, which Citi called a financing overhang. Common equity holders now sit below an instrument converting at the implied $18.36 entry price, with the stock at $14.63.
The Data Credibility Discount
Ivonescimab is licensed from Akeso, part of a wave of Western licensing of Chinese pharmaceutical assets that totaled over $120 billion in 2026, up 36% year-over-year. Goldman Sachs analyst Salveen Richter told CNBC that most Chinese drug development improves on existing drugs rather than creating first-in-class innovation, and that Chinese clinical data faces credibility questions in Western patient populations, citing HARMONi-3 in that context. Bernstein and Leerink both moved to Market Perform after the AstraZeneca deal, each citing the share price as already close to intrinsic value, more cautious than the $30 analyst consensus. The probability-weighted assumptions behind that gap are worth testing with a DCF calculator.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| SMMT | $11.7B | n/a | -27.0% |
| VKTX | $3.2B | n/a | -25.4% |
| RVMD | $38.1B | n/a | +229.5% |
| IOVA | $6.2B | n/a | +487.1% |
| IBRX | $9.7B | n/a | +274.7% |
| SRRK | $4.9B | n/a | +42.9% |
HARMONi-3 Is the Resolution Point
Jefferies upgraded Summit ahead of HARMONi-3 progression-free survival data, with Stifel and Guggenheim both setting higher price targets specifically around that readout. The trial is where the Chinese clinical data question gets answered in a Western patient population. Strong PFS data would challenge Goldman's credibility concerns and confront 26.3% short interest on a thin float. Data that fails to replicate the Akeso China results would instead support the discount the market has maintained since AstraZeneca's investment. Run the free Summit Therapeutics Inc. deep-dive → before the readout.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why does Summit trade below AstraZeneca's entry price?
Short sellers holding 26.3% of the float are skeptical about ivonescimab's Chinese clinical trial data and the risks surrounding HARMONi-3 progression-free survival. Even insider ownership at 80.9% hasn't prevented the 20% discount from AstraZeneca's $18.36 investment price to the current $14.63 trading level.
What is ivonescimab and how does it work?
Ivonescimab is a bispecific antibody developed by Summit Therapeutics that blocks PD-1, the same checkpoint targeted by Merck's Keytruda, while also cutting off blood supply to tumors. The drug is currently in Phase III clinical trials for non-small cell lung cancer and colorectal cancer.
When will Summit's stock move based on trial results?
HARMONi-3 progression-free survival data is the key catalyst that could resolve market skepticism about the drug. Jefferies upgraded Summit ahead of this readout, while Stifel and Guggenheim both set price targets specifically around the HARMONi-3 data release.
Where did ivonescimab originate?
Ivonescimab is licensed from Akeso, a Chinese pharmaceutical company, placing Summit within a broader wave of Western licensing of Chinese pharmaceutical assets that totaled over $120 billion in 2026, up 36% year-over-year. This Chinese origin is a key source of investor skepticism about the drug's clinical data credibility.
What do analysts expect Summit's stock to be worth?
Analyst consensus targets $30 per share for Summit, but Bernstein and Leerink moved to Market Perform ratings post-deal, arguing the share price is already close to intrinsic value. This more cautious stance reflects doubt about whether the Chinese clinical data will replicate successfully in Western patient populations.
AstraZeneca agreed last month to invest $2 billion in Summit Therapeutics at an implied entry price of $18.36 per share — yet SMMT trades at $14.63 today, below its strategic partner's own cost basis, while short sellers hold 26.3% of the float and analysts have converged on targets near $30.